The Hyderabad-based pharmaceutical major Dr. Reddy's Laboratories Ltd. has launched Moxifloxacin Hydrochloride tablets in 400 mg strength in the US market on March 4, 2014, following the approval by the US FDA.
Moxifloxacin hydrocloride tablets are an equivalent generic version of Avelox (Moxifloxacin Hydrochloride) tablets 400 mg and are used in the treatment of bacterial infections.
As per IMS Health data, the Avelox (Moxifloxacin Hydrochloride) tablets brand had US sales of around $195 million for the twelve months ended December 2013, the company said.
Dr. Reddy's Moxifloxacin hydrocloride tablets, 400 mg are available in bottle counts of 30.
At the BSE, Dr. Reddy's Laboratories shares are currently trading at Rs.2,826.05, up 0.84 percent from the previous close.
For comments and feedback: editorial@rttnews.com